185 related articles for article (PubMed ID: 29212964)
1. Simple Determination of Plasma Ponatinib Concentration Using HPLC.
Yasu T; Momo K; Kobayashi S; Kuroda S; Tojo A
Biol Pharm Bull; 2018 Feb; 41(2):254-258. PubMed ID: 29212964
[TBL] [Abstract][Full Text] [Related]
2. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Menna P; De Grazia U; Marchesi F; Minotti G; Salvatorelli E
Chemotherapy; 2020; 65(1-2):35-41. PubMed ID: 32829325
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
4. Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Yasu T; Momo K; Yasui H; Kuroda S
Biomed Chromatogr; 2019 Mar; 33(3):e4435. PubMed ID: 30421802
[TBL] [Abstract][Full Text] [Related]
5. Determination of the concentration of gilteritinib in human plasma using HPLC.
Yasu T; Sugi T; Momo K; Hagihara M; Yasui H
Biomed Chromatogr; 2021 Apr; 35(4):e5028. PubMed ID: 33179270
[TBL] [Abstract][Full Text] [Related]
6. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
[TBL] [Abstract][Full Text] [Related]
9. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.
Sparidans RW; Kort A; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():24-9. PubMed ID: 27179188
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance.
Abumiya M; Takahashi N; Yoshioka T; Kameoka Y; Miura M
J Clin Pharm Ther; 2021 Feb; 46(1):219-222. PubMed ID: 32985698
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients.
Abumiya M; Miura M; Takahashi N
Leuk Res; 2018 Jan; 64():42-45. PubMed ID: 29175427
[TBL] [Abstract][Full Text] [Related]
14. A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection.
Sumimoto T; Nakahara R; Sato Y; Itoh H
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374910
[TBL] [Abstract][Full Text] [Related]
15. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
19. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
20. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]